Biotechnology company ReiThera Srl reported on Tuesday that its ongoing Phase 1 study of its vaccine candidate (GRAd-COV2) against the novel coronavirus (SARS-CoV-2) is advancing on schedule.
Designed and is run jointly with the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome (Italy), this study received financial support from the Italian Ministry of Scientific Research and the Lazio Region (Rome).
Dosing and initial evaluation on the first cohort of healthy volunteers, aged between 18 and 55 years, have been completed. The company said preliminary results from this cohort, which was divided into three study arms of 15 subjects, have shown that GRAd-COV2 was well-tolerated and generated spike-binding antibodies and T-cell responses at all three doses tested.
ReiThera stated that the trial is now advancing to investigate GRAd-COV2 in the second set of three cohorts of healthy, elderly subjects, aged between 65 and 85 years. It added that results from the trial are expected to enable the selection of a vaccine dose for further investigation in a Phase 2/3 trial.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer